Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 97.50
+1.50 (1.56%)
Aug 15, 2025, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
1.77M HKD
Profits / Employee
-17.80K HKD
Market Cap
166.99B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Akeso | 3,035 |
| Sino Biopharmaceutical | 24,379 |
| WuXi Biologics | 12,575 |
| CSPC Pharmaceutical Group | 21,400 |
| Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
Innovent Biologics News
- 11 days ago - Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 - PRNewsWire
- 4 weeks ago - Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma - PRNewsWire
- 4 weeks ago - ‘China’s Ozempic’ pioneer inks deal with JD Health for online distribution - South China Morning Post
- 6 weeks ago - Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide - Seeking Alpha
- 6 weeks ago - Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms - PRNewsWire
- 7 weeks ago - Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PRNewsWire
- 7 weeks ago - Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions - PRNewsWire
- 7 weeks ago - Neutral On Innovent Biologics: Hard To Justify Its Premium - Seeking Alpha